Abstracts tagged "antibodies and systemic lupus erythematosus (SLE)"

Abstract Number: 1788 • 2016 ACR/ARHP Annual Meeting
Alterations in Sense of Smell and Limbic Structures in Patients with Systemic Lupus Erythematosus during 3-Years Follow-up
Fernando A. Peres¹, Karina de Oliveira Peliçari¹, Mariana Postal¹, Nailu A. Sinicato², Leticia Rittner³, Lilian Tereza Costallat⁴ and Simone Appenzeller⁵, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Pediatrics, State University of Campinas, Campinas, Brazil, ³UNICAMP, Sao Paulo, Brazil, ⁴RUA EZEQUIEL MAGALHAES,26, Unicamp, Campinas, Brazil, ⁵Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil
Background/Purpose: Many neurologic and neurodegenerative abnormalities are first demonstrable in the olfactory system with loss of smell up to 10 years before the onset of…
Abstract Number: 690 • 2012 ACR/ARHP Annual Meeting
Molecular Analysis of 9G4+ Antibodies in Systemic Lupus Erythematosus
Christopher Richardson¹, Asiya Seema Chida², Erin Fox¹, Lin Silver¹, Diana G. Adlowitz¹, Scott Jenks³, Elise Palmer¹, Christopher Tipton⁴ and Ignacio Sanz⁵, ¹University of Rochester, Rochester, NY, ²Medicine, Emory University Medical Center, Atlanta, GA, ³Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine/Rheumatology, Emory University, Atlanta, GA, ⁵Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Elevated titers of serum autoantibodies expressing the 9G4 idiotype are highly specific for SLE and correlate with disease activity and clinical manifestations. 9G4+ antibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].